Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
American Cancer Society. Cancer Facts and Figures 2008. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf.
[2.]
A. Jemal, et al.
Cancer statistics, 2008.
CA-A Cancer Journal for Clinicians, 58 (2008), pp. 71-96
[3.]
C.J. Ryan, E.J. Small.
Early versus delayed androgen deprivation for prostate cancer: New fuel for an old debate.
Journal of Clinical Oncology, 23 (2005), pp. 8225-8231
[4.]
N. Sharifi, et al.
Androgen deprivation therapy for prostate cancer.
JAMA, 294 (2005), pp. 238-244
[5.]
S.S. Strom, et al.
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy.
Clinical Cancer Research, 11 (2005), pp. 6889-6894
[6.]
L.K. Harle, et al.
Endocrine complications of androgen- deprivation therapy in men with prostate cancer.
Clinical Advances in Hematology & Oncology, 4 (2006), pp. 687-696
[7.]
S. Srinivas, N. Colocci.
Bone related events in high risk prostate cancer.
Journal of Urology, 176 (2006), pp. S50-S54
[8.]
F. Saad, et al.
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Journal of the National Cancer Institute, 96 (2004), pp. 879-882
[9.]
J.M. Holzbeierlein.
Managing complications of androgen deprivation therapy for prostate cancer.
Urologic Clinics of North America, 33 (2006), pp. 181-190
[10.]
S. Kojima, et al.
Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
Journal of Urology, 171 (2004), pp. 679-683
[11.]
J.D. Debes, D.J. Tindall.
Mechanisms of androgen- refractory prostate cancer.
The New England Journal of Medicine, 351 (2004), pp. 1488-1490
[12.]
E.J. Small, et al.
Antiandrogen withdrawal alone or in combination with ketoconazole in androgenindependent prostate cancer patients: A Phase III trial (CALBG 9583).
Journal of Clinical Oncology, 22 (2004), pp. 1025-1033
[13.]
J.S. Lam, et al.
Secondary hormonal therapy for advanced prostate cancer.
Journal of Urology, 175 (2006), pp. 27-34
[14.]
I. Tannock, et al.
Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response.
Journal of Clinical Oncology, 7 (1989), pp. 590-597
[15.]
K.N. Syrigos, et al.
Prostate cancer in the elderly.
Anticancer Research, 25 (2005), pp. 4527-4534
[16.]
J. Michels, K.N. Chi.
Second-line chemotherapy with mitoxantrone or docetaxel in patients with hormone-refractory prostate cancer (HRPC) after docetaxel and mitoxantrone failure.
American Journal of Hematology/Oncology, 5 (2006), pp. 555-557
Copyright © 2009. Lippincott Williams & Wilkins